SenesTech, Inc. - SNES STOCK NEWS

SenesTech (NASDAQ: SNES), a leader in rodent fertility control, has announced its collaboration with Danish company TriptoBIO to develop biosynthetic triptolide, an active ingredient in their EPA-registered contraceptive, ContraPest. This partnership aims to enhance the efficiency and cost-effectiveness of ContraPest by ensuring consistent quality and reducing production costs compared to botanically sourced triptolide from China. CEO Joel Fruendt highlighted the potential for improved market expansion and sustainability through this initiative, which aligns with the company's mission to advance pest management practices.

SenesTech, Inc. (NASDAQ: SNES) is set to release its financial results for the fourth quarter and fiscal year 2022 after market close on March 16, 2023. A conference call will follow at 5:00 pm ET to discuss the outcomes. The company's proprietary technology, ContraPest, is focused on managing rodent populations through fertility control rather than extermination. This unique approach aligns with sustainable pest management practices. Investors can join the conference call via telephone or through a live webcast available on SenesTech's Investor Relations website.

SenesTech, Inc. (NASDAQ: SNES) reported significant findings on its rodent fertility control product, ContraPest, at the recent Vertebrate Pest Conference (VPC). Major highlights include a 95% reduction in rat activity when ContraPest is used in integrated pest management programs. Independent studies also indicated a 98% decline in rat populations at an animal rescue facility and an 80% reduction at another location. Customers have noted reduced economic losses, enhancing the product's acceptance. SenesTech aims to leverage this surge for growth acceleration in 2023, supported by positive customer feedback.

SenesTech (NASDAQ: SNES) announced the appointment of Nicole Williams as its new Chief Revenue Officer as part of a broader restructuring to enhance sales and commercialization efforts. Following a year of record revenue, the company is expanding its field sales organization to seven teams and is focused on customer acquisition in 2023. An E-Commerce Manager will be incorporated to improve product education and accessibility. The CEO highlighted the goal of accelerating growth beyond a 2X growth rate after a successful 2022. The company is set to release its fourth quarter financials in March 2023.

SenesTech, Inc. (NASDAQ: SNES) announced that ContraPest, the only EPA registered contraceptive for rats, has been approved for General Use by the New York State Department of Environmental Conservation. This decision removes the "Restricted Use Pesticide" label, significantly broadening the market for ContraPest in New York, allowing non-licensed individuals to apply it. New York is now the 49th state to approve this change, joining Washington D.C. and various U.S. territories. CEO Joel Fruendt emphasized the importance of ContraPest in reducing rat populations, particularly as New York City prioritizes rat control efforts.

SenesTech, Inc. (NASDAQ: SNES) announced its participation in the Lytham Partners Investor Select Conference on January 31, 2023. The management team will host one-on-one meetings with investors and present its cutting-edge technology for controlling animal pest populations through fertility control. The live presentation will be available at 9:00 AM ET on the company’s website, alongside archived content for later viewing. Interested parties can arrange meetings through Lytham Partners. SenesTech focuses on sustainable pest control, aiming to reduce rodent populations without harmful methods, leveraging their patented product, ContraPest.

SenesTech (NASDAQ: SNES) has granted inducement equity awards to its new CEO, Joel Fruendt, and two other employees, aligning with Nasdaq Listing Rule 5635(c)(4). Fruendt received 18,799 restricted stock units and options to purchase 71,500 shares at an exercise price of $2.66. The other employees, Dan Palasky and Alice Myton, received options to purchase 26,500 and 1,000 shares, respectively. All options will vest over three years, aiming to enhance staff retention and attract talent. This strategic move underscores SenesTech's commitment to growth in rodent fertility control with their EPA registered product, ContraPest.

SenesTech (NASDAQ: SNES) has announced a significant deployment of its EPA registered contraceptive, ContraPest, at the Los Angeles Zoo. The initial rollout involves 17 bait stations, expanding to over 250 as confidence grows. ContraPest has shown up to 90% efficacy improvement over traditional pest control methods, addressing issues common to zoo environments. This deployment is part of a market expansion opportunity, as SenesTech reports that the zoo and sanctuary vertical has grown over 300% in the past year, now serving nearly 70 customers.

SenesTech (NASDAQ: SNES) closed a public offering of 1,428,572 shares at $3.50 each, generating approximately $5 million in gross proceeds. The offering included Series A and Series B warrants, both with an exercise price of $3.165, expiring five years and thirteen months respectively. Proceeds will be utilized for general corporate purposes. Additionally, existing warrants were amended to reduce their exercise price to $3.165 per share. The offering was facilitated by H.C. Wainwright & Co.